Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
73.15
+0.34 (0.47%)
At close: Aug 29, 2025, 4:00 PM
73.40
+0.25 (0.34%)
After-hours: Aug 29, 2025, 7:34 PM EDT
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Halozyme Therapeutics stock have a consensus rating of "Buy" and an average price target of $70.25, which forecasts a -3.96% decrease in the stock price over the next year. The lowest target is $53 and the highest is $80.
Price Target: $70.25 (-3.96%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Halozyme Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 1 | 1 | 1 | 3 |
| Hold | 4 | 4 | 5 | 5 | 5 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $75 → $80 | Buy | Maintains | $75 → $80 | +9.36% | Aug 18, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $60 → $63 | Hold | Maintains | $60 → $63 | -13.88% | Aug 7, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $91 → $78 | Buy | Maintains | $91 → $78 | +6.63% | Aug 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $72 → $75 | Strong Buy | Maintains | $72 → $75 | +2.53% | Aug 6, 2025 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $62 → $75 | Hold → Buy | Upgrades | $62 → $75 | +2.53% | Aug 6, 2025 |
Financial Forecast
Revenue This Year
1.35B
from 1.02B
Increased by 32.57%
Revenue Next Year
1.66B
from 1.35B
Increased by 23.25%
EPS This Year
6.26
from 3.43
Increased by 82.47%
EPS Next Year
8.07
from 6.26
Increased by 28.99%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.4B | 1.8B | |||
| Avg | 1.3B | 1.7B | |||
| Low | 1.3B | 1.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.1% | 31.9% | |||
| Avg | 32.6% | 23.3% | |||
| Low | 26.4% | 11.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.51 | 8.93 | |||
| Avg | 6.26 | 8.07 | |||
| Low | 5.94 | 7.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 89.8% | 42.6% | |||
| Avg | 82.5% | 29.0% | |||
| Low | 73.1% | 12.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.